A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults

Shiri Meron-Sudai, Valeria Asato, Amos Adler, Anya Bialik, Sophy Goren, Ortal Ariel-Cohen, Arava Reizis, Laurence A. Mulard, Armelle Phalipon, Dani Cohen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate.

Original languageEnglish
Article number35
Journalnpj Vaccines
Volume8
Issue number1
DOIs
StatePublished - Dec 2023

Fingerprint

Dive into the research topics of 'A Shigella flexneri 2a synthetic glycan-based vaccine induces a long-lasting immune response in adults'. Together they form a unique fingerprint.

Cite this